Immunome (IMNM) AI Stock Analysis

• Market Cap: $738.73M
• Dividend Yield: N/A
• Average Volume (3M): 1.03M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.86
• Revenue Growth: -13.76%
• EPS Growth: 57.73%
• Country: US
• Employees: 131
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.52
• Shares Outstanding: 87,012,330
• 10 Day Avg. Volume: 961,072
• 30 Day Avg. Volume: 1,032,900
• PEG Ratio: -0.09
• Price to Book (P/B): 2.18
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.95
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $27.00
• Price Target Upside: 218.02% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 45 Neutral
• Price Target: $8.00 ▼( -5.77% Downside)

The overall stock score for Immunome is primarily impacted by its poor financial performance and concerning valuation metrics. While technical analysis suggests some short-term bullish momentum, the long-term trends remain negative. The lack of earnings call insights and corporate events does not alter the assessment.

Positive Factors

Clinical Trials

The upcoming readout for the Phase 3 RINGSIDE trial remains on track, which is a key factor for investor interest.

Efficacy and Competitiveness

IMNM's asset varegacestat has shown increased efficacy in Phase 2 data compared to the first FDA-approved medicine for desmoid tumors.

Financial Position

The company has a strong cash position with $317.3 million in cash and cash equivalents, providing a cash runway into 2027.

Negative Factors

Commercial Uncertainty

Regarding the commercial opportunity, management notes that this will be hard to answer until the profile is known, adding that if data replicates previous results, questions will answer themselves.

Data Readout Uncertainty

The company has not guided to a timeline for a data readout from the ongoing Phase 1 trial evaluating IM-1021.

Immunome Business Overview & Revenue Model

Company Description

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

How the Company Makes Money

Immunome makes money primarily through the development and commercialization of its proprietary antibody-based therapeutics. The company generates revenue through collaborations and partnerships with larger pharmaceutical companies, licensing its technologies, and potentially through future sales of approved therapeutics. Revenue streams may include upfront payments, milestone payments, and royalties from sales if any of its drug candidates successfully reach the market. Immunome's business model relies on advancing its pipeline through clinical trials to achieve regulatory approval and subsequent commercialization, which can attract further investment and partnership opportunities.

Immunome Financial Statement Overview

Summary

Immunome is facing substantial financial challenges, with declining revenue, significant net losses, and negative cash flows. Despite a moderately stable balance sheet with positive equity, the company is heavily reliant on external financing, highlighting the need for improved revenue generation and cost management.

Income Statement

Immunome's income statement reveals a challenging financial situation with declining revenue and significant net losses. The gross profit margin has improved but remains heavily negative due to high operational costs. The net profit margin is also deeply negative, indicating continued financial strain. The company has struggled to grow its revenue, with a notable decline in the past year.

Balance Sheet

The balance sheet shows a moderate level of stability with a positive stockholders' equity. However, the debt-to-equity ratio remains low, reflecting limited leverage, which can be positive but also shows constrained access to debt financing. The equity ratio is relatively strong, indicating that the company is primarily financed by equity rather than debt.

Cash Flow

Immunome's cash flow statement highlights significant challenges, with negative operating and free cash flows indicating ongoing cash burn. The company has relied heavily on financing activities for cash flow, which may not be sustainable in the long term. The free cash flow to net income ratio is negative, underscoring the need for improved operational efficiency.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
9.04M	14.02M	0.00	0.00	0.00
	Gross Profit
9.04M	-8.91M	-631.00K	-755.00K	-755.00K
	EBIT
-305.80M	-109.53M	-36.90M	-25.20M	-12.26M
	EBITDA
-151.35M	-28.27M	-36.27M	-23.95M	-17.04M
	Net Income Common Stockholders
-292.96M	-106.81M	-37.51M	-24.47M	-17.12M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
217.30M	138.14M	20.32M	49.23M	39.77M
	Total Assets
240.24M	148.54M	24.05M	57.92M	44.52M
	Total Debt
4.83M	1.65M	293.00K	317.00K	613.00K
	Net Debt
-138.52M	-97.03M	-20.03M	-48.91M	-39.15M
	Total Liabilities
59.08M	28.66M	7.39M	9.74M	3.18M
	Stockholders Equity
181.16M	119.88M	16.65M	48.19M	41.34M
Cash Flow		Free Cash Flow
-117.97M	-8.40M	-28.94M	-18.30M	-12.72M
	Operating Cash Flow
-110.79M	-7.57M	-28.69M	-18.23M	-12.13M
	Investing Cash Flow
-85.06M	-30.48M	-248.00K	-79.00K	-586.00K
	Financing Cash Flow
240.53M	116.41M	32.00K	27.77M	49.94M

Immunome Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.49
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMNM, the sentiment is Positive. The current price of 8.49 is above the 20-day moving average (MA) of 8.18, above the 50-day MA of 7.72, and below the 200-day MA of 10.96, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 56.20 is Neutral, neither overbought nor oversold. The STOCH value of 73.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMNM.

Immunome Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHAR	72 Outperform	$718.21M	―	-6.33%	―	23.92%	-27.69%
TRVI	55 Neutral	$639.97M	―	-55.12%	―	―	-60.26%
Sector *	53 Neutral	$5.14B	3.03	-44.09%	2.83%	16.75%	-0.06%
DNTH	48 Neutral	$592.55M	―	-28.73%	―	189.31%	51.03%
IMNM	45 Neutral	$738.73M	―	-69.21%	―	-13.76%	57.73%
KALV	45 Neutral	$570.24M	―	-150.50%	―	―	-18.75%
PRTA	43 Neutral	$354.18M	―	-23.46%	―	54.55%	36.41%

Immunome Corporate Events

Immunome Expands Share Reserve in Inducement Plan

On May 8, 2025, Immunome‘s Board of Directors approved an amendment to increase the number of shares reserved under its 2024 Inducement Plan, aimed at attracting new employees. The company reported its first-quarter 2025 financial results, highlighting a net loss of $41.6 million and a cash position expected to fund operations into 2027. Immunome is progressing with its clinical trials, including the Phase 3 RINGSIDE trial for varegacestat and Phase 1 trials for IM-1021 and IM-3050, positioning itself as a leader in targeted cancer therapies.

The most recent analyst rating on (IMNM) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Immunome stock, see the IMNM Stock Forecast page.